Pharmaceuticals

Global Epkinly Market 2026–2035 growing with oncology innovation

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Epkinly Market By 2030 Starting From Its 2026 Size?

This historical expansion is attributed to a growing occurrence of non-Hodgkin lymphoma, the shortcomings of conventional chemotherapy, progress in monoclonal antibody research, an increase in approvals for targeted oncology drugs, and existing gaps in relapsed cancer treatment.

The projected growth during the forecast period is largely driven by the increasing adoption of immuno-oncology treatments, the broadening clinical applications for bispecific antibodies, improved data on patient outcomes, rising expenditure on oncology healthcare, and the expansion of specialized cancer centers. Key trends anticipated over this outlook period include immunotherapies based on bispecific antibodies, the increased availability of T-cell engaging oncology drugs, a concentrated focus on relapsed and refractory lymphomas, the administration of oncology drugs subcutaneously, and tailored treatments for hematologic cancers.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20060&type=smp

What Drivers Are Shaping The Future Growth Of The Epkinly Market?

The future expansion of the epkinly market is expected to be propelled by the increasing demand for targeted therapies. These therapies are precise medical interventions that target particular disease-causing molecules, especially in cancers, offering reduced side effects compared to conventional treatments. Their adoption is on the rise because they offer more effective, personalized therapeutic options while minimizing adverse reactions. Epkinly (epcoritamab) serves as a targeted therapy for relapsed or refractory B-cell non-Hodgkin lymphoma; it functions by attaching to CD3 on T cells and CD20 on B cells, thereby guiding the immune system to eradicate malignant B cells. As an illustration, in October 2024, data from the National Health Service, a UK-based government department, indicated that in the 2023/24 period, 14.5% of HRT (hormone replacement therapy) items were linked to an HRT prescription prepayment certificate (PPC). This figure further increased to 21% by June 2024, which is a notable increase from 9.7% observed in June 2023. Consequently, the escalating demand for targeted therapies is fueling the expansion of the epkinly market.

Which Segment Categories Define The Epkinly Market?

The epkinly market covered in this report is segmented –

1) By Indication: Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma (HGBL), Indolent Lymphoma

2) By Route Of Administration: Intravenous (IV), Subcutaneous (SC)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies

What Major Market Trends Are Driving Changes In The Epkinly Market?

A significant trend in the epkinly market involves gaining regulatory approvals for novel therapies, particularly bispecific antibody therapies, aimed at improving treatment efficacy and expanding therapeutic options. Bispecific antibody therapies are a form of immunotherapy utilizing antibodies engineered to simultaneously bind to two distinct antigens or targets. For instance, in June 2024, AbbVie Inc., a US-based biotech company, secured FDA approval for EPKINLY (epcoritamab-bysp), which stands as the first bispecific antibody for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This innovative treatment works by engaging the immune system, targeting both CD20 and CD3, and demonstrated an impressive overall response rate of 82% in its clinical trials. EPKINLY is administered subcutaneously with a step-up dosing regimen, offering a new alternative for patients who have limited other choices. This approval represents a crucial advancement in the management of follicular lymphoma, bringing hope for enhanced patient outcomes.

Who Are The Top Companies Competing In The Epkinly Market?

Major companies operating in the epkinly market are AbbVie Inc., Genmab A/S.

Read the full epkinly market report here:

https://www.thebusinessresearchcompany.com/report/epkinly-global-market-report

Which Geographic Regions Are Influencing Demand In The Epkinly Market?

North America was the largest region in the epkinly market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the epkinly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Epkinly Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20060&type=smp

Browse Through More Reports Similar to the Global Epkinly Market 2026, By The Business Research Company

Epoxy Primer Market Report 2026

https://www.thebusinessresearchcompany.com/report/epoxy-primer-global-market-report

Exchange Traded Fund Market Report 2026

https://www.thebusinessresearchcompany.com/report/exchange-traded-fund-global-market-report

Solar Epc Market Report 2026

https://www.thebusinessresearchcompany.com/report/solar-epc-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795